205 related articles for article (PubMed ID: 36449064)
1. [The new approval procedure for clinical trials of medicinal products in the European Union-challenges for the pharmaceutical industry in Germany].
Henn DK; Ruppert T
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2023 Jan; 66(1):28-37. PubMed ID: 36449064
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of clinical trials on medicinal products by ethics committees: changes due to the new EU Regulation 536/2014 (CTR) and necessary harmonization measures].
Raffauf-Seufert C; Grass G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2023 Jan; 66(1):45-51. PubMed ID: 36472643
[TBL] [Abstract][Full Text] [Related]
3. [The national legislation accompanying the approval procedure for clinical trials of medicinal products for human use under Regulation (EU) No. 536/2014].
Frech M; Dexel F; Burgard M; Seibel Y
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2023 Jan; 66(1):12-20. PubMed ID: 36525035
[TBL] [Abstract][Full Text] [Related]
4. [First experiences with the implementation of EU Regulation 536/2014 (CTR) from the perspective of non-commercial academic research].
Fuhrmann C; Reineke C; Lang B; Grählert X
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2023 Jan; 66(1):38-44. PubMed ID: 36525036
[TBL] [Abstract][Full Text] [Related]
5. [Changes in the German Medicinal Product Act imposed by the EU regulation on clinical trials].
Nickel L; Seibel Y; Frech M; Sudhop T
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):804-811. PubMed ID: 28664271
[TBL] [Abstract][Full Text] [Related]
6. [Clinical trials with investigational medicinal products-initial experiences with the new EU clinical trial regulation 536/2014 and challenges and opportunities for contract research organisations].
Chase D; Roder B; Romero Matuschek I
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2023 Jan; 66(1):21-27. PubMed ID: 36525037
[TBL] [Abstract][Full Text] [Related]
7. [Joint pilot project of the German higher federal authorities and ethics committees on implementing the EU Regulation on clinical trials].
Sudhop T; Grass G; Wessler I
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):817-825. PubMed ID: 28664274
[TBL] [Abstract][Full Text] [Related]
8. [Reorganization of the procedures and the tasks of the responsible ethics committees after the 12th AMG amendment. Concepts of the permanent working group of the medical ethics committees in Germany].
Wessler I; Burger R; Doppelfeld E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):155-67. PubMed ID: 15726456
[TBL] [Abstract][Full Text] [Related]
9. [Implementation status of Regulation EU 536/2014 in the member states].
Stahl E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):836-840. PubMed ID: 28638933
[TBL] [Abstract][Full Text] [Related]
10. [Main characteristics of the new authorisation procedure for clinical trials with medicinal products according to regulation (EU) no 536/2014 and the cooperation between the member states].
Sudhop T; Riedel C; Krafft H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2023 Jan; 66(1):3-11. PubMed ID: 36478279
[TBL] [Abstract][Full Text] [Related]
11. [More transparency in clinical research: How are the new transparency regulations assessed from the perspective of the pharmaceutical industry?].
Wachenhausen H; Peters J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2023 Jan; 66(1):60-67. PubMed ID: 36542105
[TBL] [Abstract][Full Text] [Related]
12. Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries.
Hartmann M
Trials; 2012 Apr; 13():53. PubMed ID: 22540886
[TBL] [Abstract][Full Text] [Related]
13. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of clinical trials by Ethics Committees in Germany: experience of applicants with the review of requests for opinion of the Ethics Committees - results of a survey among members of the German Association of Research-Based Pharmaceutical Companies (VFA).
Russ H; Busta S; Riedel A; Zöllner G; Jost B
Ger Med Sci; 2009 Jul; 7():Doc07. PubMed ID: 19675747
[TBL] [Abstract][Full Text] [Related]
15. [The impact of the EU Regulation 536/2014 on the tasks and functioning of ethics committees in Germany].
Hasford J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Aug; 60(8):830-835. PubMed ID: 28638934
[TBL] [Abstract][Full Text] [Related]
16. The European clinical trials regulation (No 536/2014): changes and challenges.
Scavone C; di Mauro G; Pietropaolo M; Alfano R; Berrino L; Rossi F; Tomino C; Capuano A
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1027-1032. PubMed ID: 31608706
[No Abstract] [Full Text] [Related]
17. Navigating the maze of requirements for obtaining approval of non-interventional studies (NIS) in the European Union.
Ramirez I
Ger Med Sci; 2015; 13():Doc21. PubMed ID: 26633964
[TBL] [Abstract][Full Text] [Related]
18. [Ethics committees in clinical trials involving medicinal products].
Graf von Kielmansegg S; Benda N; Grass G; Sudhop T
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2019 Jun; 62(6):706-712. PubMed ID: 31028415
[TBL] [Abstract][Full Text] [Related]
19. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
20. [Clinical trials in Germany and in the EU in the new legislative environment. An analysis from the industry's point of view].
Heidenreich K; Möritz A; Löffler H; Oberle-Rolle B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):415-22. PubMed ID: 15830252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
